Translate Bio, Inc. TBIO

Translate Bio, Inc. Revenue | TBIO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Translate Bio, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
139 M	7.8 M	1.42 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
139 M	1.42 M	49.3 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Lexicon Pharmaceuticals LXRX	49.8 M	$ 1.74	0.82 %	$ 632 M	USA
Seres Therapeutics MCRB	789 K	$ 2.85	0.34 %	$ 25.2 M	USA
Madrigal Pharmaceuticals MDGL	958 M	$ 493.62	0.1 %	$ 11.1 B	USA
MediWound Ltd. MDWD	21.8 M	$ 13.51	0.22 %	$ 368 M	Israel
Mesoblast Limited MESO	17.2 M	$ 14.22	0.99 %	$ 17.2 B	Australia
MacroGenics MGNX	150 M	$ 3.77	5.31 %	$ 238 M	USA
MeiraGTx Holdings plc MGTX	81.4 M	$ 10.92	1.2 %	$ 878 M	USA
Mirum Pharmaceuticals MIRM	521 M	$ 81.43	0.07 %	$ 4.09 B	USA
MannKind Corporation MNKD	349 M	$ 3.82	0.53 %	$ 1.17 B	USA
MediciNova MNOV	410 K	$ 1.76	0.28 %	$ 86.4 M	USA
Mereo BioPharma Group plc MREO	36.5 M	$ 0.39	2.16 %	$ 311 M	Britain
Merck & Co. MRK	65 B	$ 139.54	0.34 %	$ 349 B	USA
Marker Therapeutics MRKR	3.55 M	$ 1.06	0.95 %	$ 16.2 M	USA
Moderna MRNA	1.94 B	$ 203.21	6.95 %	$ 79 B	USA
Maravai LifeSciences Holdings MRVI	186 M	$ 8.52	7.85 %	$ 1.23 B	USA
Matinas BioPharma Holdings MTNB	1.1 M	$ 2.82	6.82 %	$ 15.4 M	USA
RAPT Therapeutics RAPT	1.53 M	-	-	$ 2.36 B	USA
Neurocrine Biosciences NBIX	2.86 B	$ 144.21	0.72 %	$ 14.3 B	USA
Nanobiotix S.A. NBTX	32.6 M	$ 25.1	0.16 %	$ 1.2 T	France
Minerva Neurosciences NERV	41.2 M	$ 3.32	1.22 %	$ 28.1 M	USA
Nektar Therapeutics NKTR	55.2 M	$ 42.22	2.2 %	$ 712 M	USA
Nkarta NKTX	115 K	$ 2.53	0.59 %	$ 187 M	USA
Nurix Therapeutics NRIX	84 M	$ 22.88	0.09 %	$ 1.98 B	USA
Nuvation Bio NUVB	62.9 M	$ 4.95	1.07 %	$ 1.69 B	USA
Novavax NVAX	1.12 B	$ 12.56	20.08 %	$ 2.03 B	USA
Novo Nordisk A/S NVO	309 B	$ 37.54	0.59 %	$ 167 B	Danmark
Novartis AG NVS	49.9 B	$ 140.93	0.01 %	$ 273 B	Schweiz
NextCure NXTC	22.4 M	$ 5.05	0.59 %	$ 14.4 M	USA
Ocugen OCGN	4.41 M	$ 1.04	1.96 %	$ 325 M	USA
Ocular Therapeutix OCUL	52 M	$ 7.25	4.17 %	$ 1.36 B	USA
Oragenics OGEN	37.7 K	$ 0.49	1.25 %	$ 1.06 M	USA
Omeros Corporation OMER	112 M	$ 18.9	1.56 %	$ 1.2 B	USA
Oramed Pharmaceuticals ORMP	2 M	$ 4.55	1.34 %	$ 188 M	Israel
Outlook Therapeutics OTLK	1.41 M	$ 0.6	0.42 %	$ 20.9 M	USA
Ovid Therapeutics OVID	7.25 M	$ 2.34	0.21 %	$ 305 M	USA
Puma Biotechnology PBYI	228 M	$ 9.67	1.68 %	$ 484 M	USA
Processa Pharmaceuticals PCSA	5 K	$ 1.49	0.62 %	$ 1.95 M	USA
Pfizer PFE	62.6 B	$ 27.41	0.02 %	$ 156 B	USA